AbbVie Research Study – Participants Needed
We are participating with AbbVie pharmaceuticals in a research study as it relates to uterine fibroids and heavy vaginal bleeding in women. In this study, patients will be given Elagolix, an oral hormonal medication shown to reduce undesired symptoms of fibroids, as well as to decrease fibroid size. This approach is much less invasive than current leading fibroid treatment and does not pose a negative consequence on future fertility.
In the study, approximately 100 women from around the US, Canada, and Puerto Rico willbe
administered different doses of Elagolix. FIH, along with all the other participating facilities, will be monitoring the progress of their patients. The outcome of this study will expand our understanding of the ideal dosage and effects of this medication.
Participants will receive complimentary treatment as well as debit card compensation. If you think you or someone you know might be a good candidate, please contact the Study Coordinator, Joycelyn, at 808-380-8234 or email@example.com.